Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

Arash Rezazadeh Kalebasty,David J Benjamin,Yohann Loriot,Dimitrios Papantoniou,Arlene O Siefker-Radtke,Andrea Necchi,Vahid Naini,Jenna Cody Carcione,Ademi Santiago-Walker,Spyros Triantos,Earle F Burgess

European Urology Open Science（2023）

引用 1|浏览3

暂无评分

摘要

This retrospective study found some evidence of potential lower response rates and shortened overall survival following anti–programmed death-(ligand) 1 therapy in patients with metastatic urothelial carcinoma with prespecified fibroblast growth factor receptor alterations (FGFRa) than in those without FGFRa who received prior immunotherapy between May 2018 and July 2019.

查看译文

关键词

Anti–programmed death-(ligand) 1 therapy,Fibroblast growth factor receptor,FGFR alteration,Programmed death-(ligand) 1,Programmed cell death protein 1,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要